3d8cce44-2cc8-464c-930c-78eb705bc4c8
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 61.2320328542094
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.590
- ANGIOGENESIS+0.460
- ALLOGRAFT_REJECTION+0.340
- MYOGENESIS+0.300
- IL6_JAK_STAT3_SIGNALING+0.270
- INFLAMMATORY_RESPONSE+0.250
- UV_RESPONSE_DN+0.250
- COAGULATION+0.220
- APICAL_JUNCTION+0.190
- COMPLEMENT+0.190
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.610
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.470
- PEROXISOME-0.460
- FATTY_ACID_METABOLISM-0.430
- MYC_TARGETS_V2-0.420
- P53_PATHWAY-0.390
- GLYCOLYSIS-0.370
- CHOLESTEROL_HOMEOSTASIS-0.350
- ESTROGEN_RESPONSE_EARLY-0.350
- ESTROGEN_RESPONSE_LATE-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 66e5440a-6b08-43cc-b007-82ac3f5221d1 | — | — | 0.894 |
| 2 | SRR6013529 | — | cohortMD2 | 0.892 |
| 3 | 17d3d480-5503-419e-92cd-cbc7db9659d2 | — | — | 0.889 |
| 4 | SRR975557 | — | — | 0.877 |
| 5 | 09f3976d-4e95-41b4-bc0b-27eea3e20bb3 | — | — | 0.873 |
| 6 | SRR33346956 | — | — | 0.871 |
| 7 | SRR12475140 | — | — | 0.871 |
| 8 | TCGA-93-A4JQ-01A-11R-A24X-07 | — | cohortA1 | 0.865 |
| 9 | 5943bf89-bad2-4461-8d80-7f9481810257 | — | — | 0.864 |
| 10 | TCGA-K4-A3WS-01A-11R-A22U-07 | — | — | 0.855 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.590 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.460 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.340 | Idelalisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.270 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.250 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| COAGULATION | 0.220 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| COMPLEMENT | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.180 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.170 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.140 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.140 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.070 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.030 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.030 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.020 | Inavolisib | — uncovered |